About This Fund
Hatch BioFund is an early-stage life sciences venture capital fund managed by Hatch BioFund Management LLC, the dedicated investment arm of the Pennsylvania Biotechnology Center (PABC) in Doylestown, Pennsylvania. The fund is targeting $50 million in capital commitments to invest in promising early-stage and seed-stage biotech, pharmaceutical, and life sciences companies operating within or affiliated with the PABC ecosystem. Named investors include the Bucks County Employees' Retirement Board ($5 million), Daiichi Sankyo Inc. ($10 million strategic commitment announced in 2021), and The Provco Group ($2 million), with the fund continuing its fundraise toward the $50 million target.
Hatch BioFund invests exclusively in private companies developing therapeutics and vaccines for human use across all treatment modalities—spanning small molecules, biologics, cell therapy, gene therapy, and RNA-based medicines. The fund's distinctive model pairs early-stage capital with access to PABC's physical infrastructure: laboratory and research facilities in the Philadelphia region, one of the fastest-growing biotech hubs in the United States, along with deep scientific advisory board expertise and PABC's established network of corporate, academic, and government partners. This integrated model is designed to de-risk translational science before clinical-stage financing requirements.
Hatch BioFund Management LLC is led by Vladimir Walko, a former West Pharmaceuticals executive and investment banker, with all investments reviewed and approved by an experienced Scientific Advisory Board and Investment Committee. The PABC's track record as a biotech incubator—housing and supporting more than 40 resident companies spanning oncology, infectious disease, medical devices, and digital health—provides Hatch BioFund with proprietary deal flow, specialist diligence support, and co-development relationship potential with strategic LP partners such as Daiichi Sankyo.